ethyl (7E)-2-amino-7-hydroxyimino-5,6-dihydro-4H-1-benzothiophene-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: ethyl (7E)-2-amino-7-hydroxyimino-5,6-dihydro-4H-1-benzothiophene-3-carboxylate
• 化学式: C₁₁H₁₄N₂O₃S
• 分子量: 254.31
• InChiKey: BJALSKIJKIIOIX-NTUHNPAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Small molecule anti-scarring agents
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US10548911B2

  公开（公告）日：2020-02-04

  Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGFβ, as well as methods of identifying a compound that inhibits TGFβ-mediated expression of the detectable expression product.

  公开了治疗有需要的患者纤维化的方法，包括向患者施用一定量的本文所确定的活性剂，该活性剂对抑制肌成纤维细胞的形成从而治疗纤维化具有治疗效果。还公开了一种重组细胞系，该细胞系包括以对TGFβ的剂量依赖性反应表达可检测表达产物的重组基因，以及鉴定抑制TGFβ介导的可检测表达产物表达的化合物的方法。
• SMALL MOLECULE ANTI-SCARRING AGENTS
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20170216332A1

  公开（公告）日：2017-08-03

  Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGFβ, as well as methods of identifying a compound that inhibits TGFβ-mediated expression of the detectable expression product.
• [EN] SMALL MOLECULE ANTI-SCARRING AGENTS<br/>[FR] AGENTS ANTI-CICATRICES FORMÉS DE PETITES MOLÉCULES
  申请人：UNIV ROCHESTER

  公开号：WO2015195684A2

  公开（公告）日：2015-12-23

  Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGFβ, as well as methods of identifying a compound that inhibits TGFβ,-mediated expression of the detectable expression product.